lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
=== Reactivation and transplantation === The specific triggers for reactivation are not well understood. Some researchers have suggested that injury, physical or emotional stress, and hormonal imbalances could be involved. Researchers during 2011 discovered that reactivation can positively be triggered in vitro by histone deacetylase inhibitors. Once reactivation begins, the rolling circle process is initiated and concatemers are formed as described above. A study published in The Journal of Infectious Diseases in 2024 investigated the reactivation of inherited chromosomally integrated human herpesvirus 6 (iciHHV-6B) in a liver transplant recipient and its impact on the graft. The research, conducted by Hannolainen et al., used hybrid capture sequencing and various molecular techniques to analyze the viral sequences and host immune response. The findings demonstrated active replication of iciHHV-6B and significant immune activation, suggesting the pathological impact of viral reactivation on transplant outcomes. The study emphasizes the importance of monitoring iciHHV-6 reactivation in transplant patients.
cytidine (C, Cyd) One of the four standard nucleosides used in RNA molecules, consisting of a cytosine base with its N9 nitrogen bonded to the C1 carbon of a ribose sugar. Cytosine bonded to deoxyribose is known as deoxycytidine, which is the version used in DNA.
Molecular sequence analysis: With rapid development of DNA sequencing technology, an enormous amount of DNA sequence data is available and even more is forthcoming in the future. Various methods have been developed to infer the DFE from DNA sequence data. By examining DNA sequence differences within and between species, we are able to infer various characteristics of the DFE for neutral, deleterious and advantageous mutations. To be specific, the DNA sequence analysis approach allows us to estimate the effects of mutations with very small effects, which are hardly detectable through mutagenesis experiments. One of the earliest theoretical studies of the distribution of fitness effects was done by Motoo Kimura, an influential theoretical population geneticist. His neutral theory of molecular evolution proposes that most novel mutations will be highly deleterious, with a small fraction being neutral. A later proposal by Hiroshi Akashi proposed a bimodal model for the DFE, with modes centered around highly deleterious and neutral mutations. Both theories agree that the vast majority of novel mutations are neutral or deleterious and that advantageous mutations are rare, which has been supported by experimental results. One example is a study done on the DFE of random mutations in vesicular stomatitis virus. Out of all mutations, 39.6% were lethal, 31.2% were non-lethal deleterious, and 27.1% were neutral. Another example comes from a high throughput mutagenesis experiment with yeast.
In late November Peter Levene, Chief of Procurement, had a meeting at the Ministry of Defence with his French, German and Italian counterparts (the National Armaments Directors) and the representatives of the consortium, and agreed to "buy European" for certain classes of helicopters, although Heseltine was not actually present. The meeting was later praised by the House of Commons Defence Select Committee. Thatcher, who only learned of the meeting through Cuckney, was displeased, as were Brittan and the Treasury, who thought the US option might be cheaper.
Pea protein is rich in nutrients such as protein and carbohydrates. Pea protein also contains vitamins and minerals and is low in fat. While generally rich in protein, the actual protein content of peas is variable and influenced by both genetic factors and environmental factors (such as soil and climate in which the peas are cultivated). Typically, peas contain 23.1–30.9% protein, 1.5–2.0% fat, and minor constituents such as vitamins, phytic acid, saponins, polyphenols, minerals, and oxalates. They also contain several classes of protein: globulin, albumin, prolamin, and glutelin. The proteins are mainly albumins and globulins, which account for 10-20% and 70-80% of the protein in the pea seed, respectively. The albumins are water-soluble and considered the metabolic and enzymatic proteins, while the globulins are salt soluble and act as the storage proteins for the seed. Globulins can be further classified into legumin and vicilin, which belong to the 11S and 7S seed storage protein classes, respectively. Legumin is a hexameric protein, and vicilin proteins are trimers. Pea protein is considered to be a complete protein, containing all the essential amino acids. However, it is not balanced, as it has high levels of lysine and threonine but relatively low amounts of sulfur-containing amino acids including cysteine and methionine. Pea seeds contain 60-65% carbohydrates mainly composed of oligosaccharides, monosaccharides, polysaccharides, and disaccharides. The major carbohydrate fraction in peas is starch, which is the major storage carbohydrate in the cotyledons.
Sources: en.wikipedia.org
Biden also faced significant opposition from uncommitted voters and the Uncommitted National Movement in their protest vote movement against Biden due to his support for Israel during the Gaza war, which collectively won 36 delegates. Following a "disastrous" June 2024 debate performance against Trump that "inflamed age concerns", Biden ultimately withdrew from the race on July 21, 2024, and immediately endorsed Kamala Harris to replace him in his place as the party's presidential nominee. Harris quickly announced her own presidential campaign later that day and by the next day, Harris had secured the non-binding support of enough uncommitted delegates that were previously pledged to Biden to make her the party's presumptive nominee. Biden's withdrawal made him the first eligible incumbent president since Lyndon B. Johnson in 1968 not to seek re-election, and the first to withdraw after securing enough delegates to win the nomination. Harris is the first presidential nominee who did not participate in the presidential primaries since Vice President Hubert Humphrey, also in 1968, and the first since the modern Democratic Party primary procedure was created in 1972 (prior to which most states did not hold primary elections). On August 5, 2024, after five days of online balloting, Democratic National Convention delegates voted to make Harris the party's 2024 presidential nominee. She selected Minnesota Governor Tim Walz as her running mate the following day and accepted the party's nomination on August 22.
Eastern Theater Command Southern Theater Command Western Theater Command Northern Theater Command Central Theater Command The service headquarters retain operational control in some areas within China and outside of China. For example, army headquarters controls or is responsible for the Beijing Garrison, the Tibet Military District, the Xinjiang Military District, and border and coastal defences. The counterpiracy patrols in the Gulf of Aden are controlled by navy headquarters. The JSD nominally controls operations beyond China's periphery, but in practice this seems to apply only to army operations. Services and theater commands have the same grade. The overlap of areas or units of responsibility may create disputes requiring CMC arbitration. As part of the 2015 reforms, military regions were replaced by theatre commands in 2016. Military regions were − uinlike the theatre commands − army-centric peacetime administrative organizations, and joint wartime commands were created on-demand by the army-dominated General Staff Department.
Goenrich M, Bartoschek S, Hagemeier CH, Griesinger C, Vorholt JA (February 2002). "A glutathione-dependent formaldehyde-activating enzyme (Gfa) from Paracoccus denitrificans detected and purified via two-dimensional proton exchange NMR spectroscopy". The Journal of Biological Chemistry. 277 (5): 3069–72. doi:10.1074/jbc.C100579200. hdl:11858/00-001M-0000-0012-F447-8. PMID 11741920.
=== Safe handling in health care settings === As of 2018, there were no occupational exposure limits set for antineoplastic drugs, i.e., OSHA or the American Conference of Governmental Industrial Hygienists (ACGIH) have not set workplace safety guidelines.
Time-resolved mass spectrometry (TRMS) is a strategy in analytical chemistry that uses mass spectrometry platform to collect data with temporal resolution. Implementation of TRMS builds on the ability of mass spectrometers to process ions within sub-second duty cycles. It often requires the use of customized experimental setups. However, they can normally incorporate commercial mass spectrometers. As a concept in analytical chemistry, TRMS encompasses instrumental developments (e.g. interfaces, ion sources, mass analyzers), methodological developments, and applications.
Sources: en.wikipedia.org
Alprenolol, or alfeprol, alpheprol, and alprenololum (Gubernal, Regletin, Yobir, Apllobal, Aptine, Aptol Duriles), is a non-selective beta blocker as well as a 5-HT1A and 5-HT1B receptor antagonist, used in the treatment of angina pectoris. It is no longer marketed by AstraZeneca, but may still be available from other pharmaceutical companies or generically.
Strontium-90 is a radioactive fission product produced by nuclear reactors used in nuclear power. It is a major component of high-level radioactivity of nuclear waste and spent nuclear fuel. Its 29-year half-life is short enough that its decay heat has been used to power arctic lighthouses, but long enough that it can take hundreds of years to decay to safe levels. Exposure from contaminated water and food may increase the risk of leukemia, bone cancer and primary hyperparathyroidism.
== Double meaning == The use of the word "faggot" has caused misunderstanding due to its meaning as a pejorative term for a homosexual man. In 2004, a radio commercial for the UK supermarket chain Somerfield, in which a man rejects his wife's suggested dinner saying "I've got nothing against faggots, I just don't fancy them" was found to have been innuendo which breached the Advertising and Sponsorship Code and was banned by the industry regulator Ofcom. Additionally, the term caused multiple instances of the scunthorpe problem, where profanity filters erroneously blocked the term regardless of its use in context. In November 2013, it was reported that British Facebook users had been blocked temporarily for using the word, in its culinary sense, on the website. Facebook said that the word had been misinterpreted. In September 2019, a Google Ads advertisement for a British cafe was removed for featuring the term.
Sumatriptan is structurally similar to the neurotransmitter serotonin (5-HT) and acts as an agonist of the serotonin 5-HT1B, 5-HT1D, and 5-HT1F receptors. Sumatriptan's primary therapeutic effect is related in its inhibition of the release of calcitonin gene-related peptide (CGRP), likely through its 5-HT1D/1B receptor agonist action. This has been substantiated by the efficacy of more recently developed CGRP targeting drugs and antibodies developed for the preventive treatment of migraine. How agonism of the 5-HT1D/1B receptors inhibits CGRP release is not fully understood. CGRP is believed to cause sensitization of trigeminal nociceptive neurons, contributing to the pain experienced in migraine. Sumatriptan is also shown to decrease the activity of the trigeminal nerve, which presumably accounts for sumatriptan's efficacy in treating cluster headaches. The injectable form of the drug has been shown to abort a cluster headache within 30 minutes in 77% of cases. Sumatriptan does not affect oxytocin or vasopressin levels in humans.
The functional group of nitriles containing the C≡N triple bond is referred to as the nitrile or cyano group. If the nitrile is the highest-ranking functional group, the suffix -nitrile is added to the name of the parent compound. The triply bonded carbon atom is, as always, included in the parent chain. Alternatively, the ending -carbonitrile may be used (analogous to -carboxylic acid), in which case the carbon atom is not counted as part of the parent chain. This ending must be used if the nitrile group is attached to a ring (as in cyclopentanecarbonitrile) or if not all carbon atoms are part of the parent chain, which is necessarily the case when more than two nitrile groups are present, as these can only be located at the termini of the chain. Due to their relationship to carboxylic acids (the nitrile carbon has the same oxidation state as the carboxyl carbon), trivial names are often derived from the corresponding carboxylic acids using the ending -onitrile (for example, benzoic acid to benzonitrile). If the nitrile function is not the principal functional group in the molecule, the prefix cyano- is used together with the appropriate locant. In this case as well, the triple-bonded carbon atom is not counted as part of the parent chain.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.